Original research / IX Biopharma

iX Biopharma’s Revenue Rose, but Its Cash Use Keeps Dividends Off the Table

Development work lifted iX Biopharma’s quarterly revenue, but operating cash outflow widened and its cash balance fell. The company declared no dividend for the September 2026 quarter.

Dividends.sg ·

iX Biopharma (SGX: 42C) reported higher revenue for the quarter ended 30 September 2026, yet its business used substantially more cash. For a dividend investor, that gap matters more than the sales increase. In its unaudited results announced on 11 November, the company said it had declared or recommended no dividend because it needed to conserve cash for product development and commercialisation. [S1, p. 1] [S1, p. 5] [S1, p. 18]

Development work lifted revenue

Group revenue rose to S$2.71 million from S$1.60 million a year earlier. S$1.77 million came from development services for Wafermine, a treatment under development for acute moderate to severe pain. That work accounted for about 65% of the quarter’s revenue. Meanwhile, medicinal cannabis revenue fell from S$1.02 million to S$0.64 million, and nutraceutical revenue fell from S$0.51 million to S$0.25 million. The company attributed those declines to softer Australian conditions and reduced production capacity during an equipment move, respectively. [S1, p. 8] [S1, p. 15]

Gross profit increased to S$1.75 million from S$0.48 million, but the group’s loss widened to S$3.33 million from S$0.57 million. Expenses included S$0.80 million of share-based compensation and S$0.57 million of relocation and restructuring costs. Those items help explain the accounting loss, but setting them aside would not establish that the business is generating cash for dividends. [S1, p. 2] [S1, p. 8] [S1, p. 15]

Cash use is the harder test

Net cash used in operating activities was S$2.32 million, against S$0.08 million in the comparable quarter. Add S$0.07 million spent on property, plant and equipment, and operating and investing activities together used S$2.39 million. The cash-flow statement also records S$1.51 million received from warrant exercises and S$2.29 million of borrowing repayments during the quarter. [S1, p. 5]

Group cash and cash equivalents on the balance sheet fell from S$14.74 million at 30 June to S$11.36 million at 30 September. The September figure included S$0.60 million of bank deposits pledged as security, which the cash-flow statement excludes from its closing cash figure. A sizeable balance remains, but the quarter shows cash being consumed while the company funds its development and commercial plans. [S1, p. 3] [S1, p. 9]

Debt fell, with a later share settlement

Borrowings and lease liabilities fell from S$5.80 million at 30 June to S$3.44 million at 30 September. The company says a borrowing due in July was repaid. It also disclosed a separate settlement after the quarter: on 9 October it issued 2,682,779 shares to settle an A$1.7 million loan. The September debt figure is therefore a quarter-end snapshot; the later settlement used shares rather than another cash repayment. [S1, p. 10] [S1, p. 12]

The quarter’s warrant exercises had already added 25,103,061 ordinary shares. Share funding and debt converted into shares can preserve cash, but they also increase the share count. Investors weighing a future payout should consider both cash generation and the number of shares among which any dividend would be divided. [S1, p. 11] [S1, p. 12]

What would change the dividend picture?

The company’s answer for this quarter is clear: no dividend, with cash reserved for development and commercialisation. Revenue from the Wafermine programme is progress, but the next useful evidence is whether it can be collected and converted into sustained operating cash flow while spending is brought under control. Until then, the higher revenue does not by itself make a payout more likely. [S1, p. 5] [S1, p. 15] [S1, p. 18]